It supports FDA's post-marketing safety surveillance program for drugs and therapeutic biologic products once they are on sale. FDA is now folding FAERS into a new, wider platform, the Adverse Event Monitoring System, or AEMS, which will cover all FDA-regulated products.1 FDA describes AEMS as one platform replacing several separate reporting systems, for medicines, vaccines, devices, tobacco, food, cosmetics and veterinary products, with standard reporting formats and tools such as automated redaction. It will also handle consumer complaints and whistleblower submissions.1
What it holds
Reports come from drug makers, health care providers and consumers. Events and medication errors are coded with a standard medical dictionary called MedDRA, and the database follows international safety reporting rules. FDA offers a public dashboard for searching the reports, so that anyone can look up what has been reported for a given drug, and it publishes the raw data files every quarter for researchers.1,2
What a report does not show
FDA is explicit about the limits:2
- A report does not establish cause. The event may come from the disease being treated, another drug or something else; reports reflect only the reporter's observations and opinions.
- Reports are not verified. Submitting one does not mean the information has been medically confirmed.
- Duplicates and gaps. Many reports are duplicated and some are incomplete.
- No rates. The reports cannot be used to estimate how often an event happens.
The GLP-1 labels say the same about reactions reported after approval: they come voluntarily from a population of uncertain size, so it is not always possible to estimate their frequency reliably or to establish a link to the drug.3 That is why reactions such as ileus appear on the labels without a percentage. Rates come from controlled trials instead: in the trials behind the Wegovy label, nausea was reported by 44% of people on Wegovy 2.4 mg and 16% on placebo, and vomiting by 24% and 6%.4 The Ozempic label's list of reactions reported after approval shows what such reports add. It includes acute and necrotizing pancreatitis, sometimes fatal; ileus, intestinal obstruction and severe constipation with impaction; and allergic reactions including anaphylaxis. It also lists gallbladder inflammation and removal, acute kidney injury, hair loss, and pulmonary aspiration during anesthesia.3
From reports to safety signals
FDA posts quarterly reports listing potential signals of serious risks found wholly or partly in the data, for prescription and nonprescription drugs and for biological products. A drug's appearance on that list does not mean FDA has concluded it causes the risk; it means FDA is evaluating a signal. If the evaluation confirms a link, FDA may require label changes, a risk management program, or more data, and may issue public communications.5
GLP-1 medicines in the data
FDA has used its adverse event reports to describe problems with compounded GLP-1 products. By May 31, 2026 it had received 990 reports about compounded semaglutide and more than 730 about compounded tirzepatide. It says the real number is probably higher, because state-licensed pharmacies that are not outsourcing facilities are not required to send it reports.6 Those counts show that problems are being reported; they cannot show how common the problems are among all users, because no one knows how many people took the products. Our page on compounded semaglutide covers what FDA found.
How to report
The GLP-1 labels list how to report suspected adverse reactions: to the maker, or to FDA through MedWatch at 1-800-FDA-1088 or www.fda.gov/medwatch.3 FDA says complete, detailed reports are what help it most, and that patients should talk to their doctor before stopping or changing a medicine.2
Sources
- U.S. Food and Drug Administration. FDA Adverse Event Reporting System (FAERS) and Adverse Event Monitoring System (AEMS). Content current as of March 11, 2026, read November 20, 2026. fda.gov
- U.S. Food and Drug Administration. FDA Adverse Event Monitoring System (AEMS) public dashboard. Content current as of March 11, 2026, read November 20, 2026. fda.gov
- OZEMPIC (semaglutide) injection prescribing information, NDA 209637/S-039, revised May 2026. U.S. Food and Drug Administration; highlights and section 6.2. accessdata.fda.gov
- WEGOVY (semaglutide) injection prescribing information. Novo Nordisk; DailyMed, version 19, published June 30, 2026; section 6.1, Table 3. dailymed.nlm.nih.gov
- U.S. Food and Drug Administration. Potential signals of serious risks or new safety information identified from the adverse event reporting system. Content current as of September 30, 2026, read November 20, 2026. fda.gov
- U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss. Content current as of October 1, 2026. fda.gov
Related analyses
Compounded semaglutide and tirzepatide in 2026: what FDA allows, what it has reported, and what to check
Ozempic side effects: how common each one is by dose, and when they ease
Mounjaro side effects: how common each one is by dose, and when they ease
Nausea on a GLP-1: how common, how long, when it peaks and what helps
Log side effects with dates and doses, so any report you or your doctor file is complete.
Open Dose Insider